A recent RCT showed that in HD patients with anemia and vitamin D deficiency, vitamin D therapy (50,000 IU/month) for 6 months was associated with improved Hb levels and decreased dosages of erythropoietin agents [102]. The gene discussed is GSTM1; the disease is vitamin D deficiency.